Overview

A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy

Status:
Withdrawn
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether preoperative pegaptanib sodium safely improves vitreous hemorrhage prior to surgical intervention and to evaluate the stability of pre-existing tractional retinal detachment.
Phase:
Phase 3
Details
Lead Sponsor:
Greater Houston Retina Research